Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Aveanna Healthcare Holdings Fourth Quarter 2025 Earnings Call - Preferred payer push and rate gains are normalizing volumes and margins
Aveanna closed 2025 with clear evidence that its preferred payer strategy and targeted rate wins are converting into revenue, margin and cash flow recovery, even as the company continues to wrestle wi...
- Q4 revenue was $662.5 million, up 27.4% year over year; full year 2025 revenue was $2.433 billion, up 20.2%.
- Q4 Adjusted EBITDA was $85 million, up 54% year over year; full year 2025 Adjusted EBITDA was $320.8 million, up 74.8%.
- Results benefitted from a 53rd week in the fiscal year, which boosted revenue and earnings versus a typical year.
- +16 more takeaways
"Cardinal Infrastructure Group" Full Year 2025 Earnings Call - Record $682M Backlog and M&A plus vertical integration power a 2026 guide above 20% adjusted EBITDA
Cardinal closed 2025 with a strong growth burst, a December IPO, and a company-record $682 million backlog, then quickly bolted on a large Georgia acquisition to push 2026 guidance toward $665 million...
- Revenue grew 45% in 2025 to $456 million, with approximately 33% organic growth year-over-year.
- Company completed its IPO in December 2025, and raised nearly $140 million through financing activities during the year.
- Year-end backlog hit a company record $682 million, roughly 1.5x 2025 revenue, providing strong coverage for 2026 guidance.
- +14 more takeaways
Lifezone Metals 2025 Full Year Earnings Call - Kabanga on the cusp of FID as strategic funding and project finance paths converge
Lifezone presented a tightly scripted march toward a final investment decision for the Kabanga Nickel Project. The company published a bankable feasibility study in July 2025 showing a $1.58 billion a...
- Feasibility study published July 2025 yields after-tax NPV of $1.58 billion and a 23.3% IRR, placing Kabanga in the lower quartile cost curve versus peers.
- Lifezone has completed resettlement actions and S-K 1300 initial assessment, advancing development readiness and social license in Tanzania.
- A $60 million senior secured bridge facility from Taurus Mining Finance is ring-fenced for Kabanga; $20 million drawn in 2025 and a further $5 million drawn as a subsequent event.
- +12 more takeaways
Darden Restaurants Fiscal 2026 Q3 Earnings Call - Same-Restaurant Sales Outperformance Widens, Guidance Raised
Darden reported a strong Fiscal 2026 third quarter, with total sales of $3.3 billion (up 5.9%) and same-restaurant sales up 4.2%, widening its outperformance versus the casual dining benchmark. Manage...
- Q3 results: Total sales $3.3 billion, up 5.9% year-over-year; same-restaurant sales +4.2% and outperformed the Black Box Intelligence casual dining benchmark by ~540 basis points.
- Company raised full-year cadence: now expects FY26 total sales growth of ~9.5%, same-restaurant sales ~4.5%, about 70 new restaurant openings, commodities inflation ~4%, and adjusted diluted EPS $10.57-$10.67 (includes ~ $0.25 from a 53rd week).
- Q4 implied guide: total sales growth 13.0%-14.5% (includes extra week), same-restaurant sales 3.5%-5.0%, and adjusted diluted EPS $3.59-$3.69.
- +14 more takeaways
Destination XL Group Q4 2025 Earnings Call - FiTMAP rollout and FullBeauty merger provide strategic runway as comps lag
Destination XL closed FY25 with comps that kept the chain in retreat, reporting Q4 comparable sales down 7.3% and full-year comps down 8.4%, hit hardest by a January Arctic storm that knocked a third ...
- Comparable sales declined 7.3% in Q4 2025, with stores down 8.6% and direct down 4.3%; full-year comparable sales fell 8.4%.
- January was heavily impacted by severe Arctic weather, pushing January comps to minus 12.9%; management reports a rebound with February at minus 1.3% and March following a similar trend.
- Management expects comps to improve through H1 2026, target break even before summer, and turn positive later in the year; no formal fiscal 2026 guidance will be issued until after the FullBeauty merger closes.
- +12 more takeaways
ACCESS Newswire Q4 2025 Earnings Call - Subscription Pivot and Product-Led ARR Lift
ACCESS Newswire closed 2025 as a leaner, subscription-first company, delivering flat top-line but clear product momentum. Q4 revenue was $5.8 million, gross margin held at 77%, adjusted EBITDA remaine...
- Q4 revenue was $5.8 million, essentially flat sequentially and roughly flat year-over-year; full year 2025 revenue was $22.6 million, down about 2% from 2024.
- Gross margin improved to 77% in Q4 and for the full year, up from 75%/76% in the comparable 2024 periods, attributed to headcount efficiencies and fixed-cost leverage, partially offset by higher distribution spend.
- Adjusted EBITDA for Q4 was $881,000 (15% of revenue), roughly flat year-over-year; full-year adjusted EBITDA rose to $3.2 million or 14% of revenue, showing margin progress despite flat revenue.
- +12 more takeaways
NeurAxis Q4 2025 Earnings Call - CPT Code Flip, Payer Coverage Remains the Gatekeeper for IB-Stim Growth
NeurAxis framed Q4 and early 2026 as the moment the IB-Stim commercialization story moves from access creation to execution. A Category I CPT code effective January 1, 2026, plus new payer wins and a ...
- Category I CPT code for IB-Stim became effective January 1, 2026, shifting the company from access creation to commercial execution.
- NeurAxis added roughly 45 million covered lives via a major national insurer policy in December 2025, bringing total covered lives above 100 million for PENFS/IB-Stim.
- Payers do not provide coverage based solely on the CPT code, written medical policy coverage remains essential to reimbursement and volume.
- +16 more takeaways
Taysha Gene Therapies Full Year 2025 Earnings Call - FDA alignment and REVEAL pivotal launch set a possible 6-month pathway to BLA
Taysha presented a tightly choreographed advance toward registration for TSHA-102, anchored by FDA written alignment on trial design, CMC comparability, and a 6-month interim analysis for the REVEAL p...
- Taysha initiated the REVEAL pivotal trial in Q4 2025 and has dosed multiple patients, with company guidance to complete pivotal and ASPIRE dosing in Q2 2026.
- FDA provided written alignment on the REVEAL pivotal and ASPIRE trial designs, including acceptance of a 6-month interim analysis for the REVEAL pivotal trial.
- TSHA-102 has Breakthrough Therapy designation from the FDA, granted in September 2025.
- +12 more takeaways
Chicago Atlantic BDC, Inc. Q4 2025 Earnings Call - High-yield, low-leverage cannabis-focused BDC signals readiness while markets fret about private credit
Chicago Atlantic reported Q4 2025 NII of $0.36 per share and $1.45 for the year, underscoring a high-yield, low-leverage strategy centered on senior secured debt to largely cannabis and lower middle m...
- Q4 2025 net investment income was $0.36 per share, and $1.45 for the full year.
- Management cites a yield to book value of 2.7% for Q4 and 11% for the full year as evidence of the business model.
- Gross weighted average yield on debt investments was 15.8%, versus the average public BDC yield of 10.8% cited by management.
- +15 more takeaways
Datavault AI Q4 2025 Earnings Call - Reiterates $200M 2026 Revenue Target as NYIAX, IBM and Fiserv Fuel Tokenization Push
Datavault AI closed 2025 claiming a turning point. Management reported the company’s first GAAP profitable quarter with adjusted EBITDA north of $8 million, pared down debt and more than $115 million ...
- Company reported its first ever profitable GAAP quarter in Q4 2025, with adjusted EBITDA exceeding $8 million.
- Management said it substantially eliminated debt and finished the year with over $115 million in working capital.
- Datavault reiterated full-year 2026 revenue guidance of $200 million, expecting sequential growth each quarter and a majority of revenue weighted to H2 2026.
- +14 more takeaways